Role of microRNA in predictingclinical efficacy of neoadjuvant chemoradiotherapy for rectal cancer

中华放射肿瘤学杂志 Pub Date : 2020-03-15 DOI:10.3760/CMA.J.ISSN.1004-4221.2020.03.016

Wenyan Yao, Q. Peng, Yaqun Zhu, Ye Tian

{"title":"Role of microRNA in predictingclinical efficacy of neoadjuvant chemoradiotherapy for rectal cancer","authors":"Wenyan Yao, Q. Peng, Yaqun Zhu, Ye Tian","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.016","DOIUrl":null,"url":null,"abstract":"Neoadjuvant chemoradiotherapy (NCRT) has become the standard treatment for patients with locally advanced rectal cancer (LARC). However, the response to NCRT varies among LARC patients and a subset of patients show resistance to NCRT. NCRT may delay the timing of surgery and even reduce the overall survival. Therefore, it is of significance to identify biomarkers for predicting the clinical efficacy of NCRT, screen patients who are resistant to NCRT and perform surgery as early as possible, eventually establishing an individualized therapeutic strategy. MicroRNAs are a class of small non-coding RNAs that post-transcriptionally regulate gene expression, which areinvolved in multiple signaling pathways and DNA damage repair process and affect the radiosensitivity of rectal cancer cells. Many recent studies have evaluated the role of microRNA in predicting the response to NCRT. The purpose of this article is to review the research progress and validate the role of microRNA in predicting the clinical efficacy of NCRT for rectal cancer. \n \nKey words: \nRectal neoplasm/neoadjuvant chemoradiotherapy; MicroRNA; Predict","PeriodicalId":10288,"journal":{"name":"中华放射肿瘤学杂志","volume":"29 1","pages":"229-232"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华放射肿瘤学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Neoadjuvant chemoradiotherapy (NCRT) has become the standard treatment for patients with locally advanced rectal cancer (LARC). However, the response to NCRT varies among LARC patients and a subset of patients show resistance to NCRT. NCRT may delay the timing of surgery and even reduce the overall survival. Therefore, it is of significance to identify biomarkers for predicting the clinical efficacy of NCRT, screen patients who are resistant to NCRT and perform surgery as early as possible, eventually establishing an individualized therapeutic strategy. MicroRNAs are a class of small non-coding RNAs that post-transcriptionally regulate gene expression, which areinvolved in multiple signaling pathways and DNA damage repair process and affect the radiosensitivity of rectal cancer cells. Many recent studies have evaluated the role of microRNA in predicting the response to NCRT. The purpose of this article is to review the research progress and validate the role of microRNA in predicting the clinical efficacy of NCRT for rectal cancer. Key words: Rectal neoplasm/neoadjuvant chemoradiotherapy; MicroRNA; Predict

查看原文本刊更多论文

microRNA在预测直肠癌新辅助放化疗临床疗效中的作用

新辅助放化疗(NCRT)已成为局部晚期直肠癌(LARC)患者的标准治疗方法。然而，LARC患者对NCRT的反应各不相同，一部分患者对NCRT有耐药性。NCRT可能会延迟手术时间，甚至降低总生存率。因此，鉴别生物标志物对预测NCRT临床疗效，筛选耐药患者并尽早进行手术治疗，最终制定个体化治疗策略具有重要意义。MicroRNAs是一类转录后调控基因表达的小分子非编码rna，参与多种信号通路和DNA损伤修复过程，影响直肠癌细胞的放射敏感性。最近的许多研究已经评估了microRNA在预测NCRT疗效中的作用。本文旨在综述相关研究进展，验证microRNA在预测直肠癌NCRT临床疗效中的作用。关键词:直肠肿瘤/新辅助放化疗;微rna;预测

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华放射肿瘤学杂志

自引率

0.00%

发文量

6375

期刊介绍： The Chinese Journal of Radiation Oncology is a national academic journal sponsored by the Chinese Medical Association. It was founded in 1992 and the title was written by Chen Minzhang, the former Minister of Health. Its predecessor was the Chinese Journal of Radiation Oncology, which was founded in 1987. The journal is an authoritative journal in the field of radiation oncology in my country. It focuses on clinical tumor radiotherapy, tumor radiation physics, tumor radiation biology, and thermal therapy. Its main readers are middle and senior clinical doctors and scientific researchers. It is now a monthly journal with a large 16-page format and 80 pages of text. For many years, it has adhered to the principle of combining theory with practice and combining improvement with popularization. It now has columns such as monographs, head and neck tumors (monographs), chest tumors (monographs), abdominal tumors (monographs), physics, technology, biology (monographs), reviews, and investigations and research.